C130039O16Rik Inhibitors
C130039O16Rik, a gene product of the RIKEN cDNA C130039O16, is an enigmatic protein intricately involved in crucial cellular pathways. Its functions are not yet fully elucidated, but existing data suggests participation in signaling cascades such as MAPK/ERK, PI3K-AKT, JNK, and potentially others. Positioned at the intersection of these pathways, C130039O16Rik may play roles in regulating cellular responses, gene expression, and possibly cellular differentiation and survival.
In the realm of C130039O16Rik inhibitors, understanding the broader context of cellular signaling becomes imperative. The inhibitors listed, targeting key pathways like MAPK/ERK, PI3K-AKT, JNK, and NF-κB, can indirectly impact C130039O16Rik by disrupting these intricate cascades. For instance, MEK inhibitors like U0126 and PD98059 alter the MAPK pathway, potentially influencing cellular differentiation mechanisms linked to C130039O16Rik. Similarly, PI3K inhibitors like LY294002 and Wortmannin may indirectly modulate C130039O16Rik by perturbing the PI3K-AKT pathway, affecting cell survival. The comprehensive exploration of these inhibitors provides a nuanced understanding of potential regulatory mechanisms associated with C130039O16Rik, contributing to the broader landscape of cellular signaling research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, targets RAF kinases in the MAPK pathway. By disrupting downstream signaling, it indirectly modulates C130039O16Rik, impacting cellular proliferation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, affecting the PI3K-AKT pathway. Its interference in this cascade has potential repercussions on C130039O16Rik, contributing to alterations in cell survival mechanisms. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts JNK signaling. Its influence on JNK pathways can indirectly affect C130039O16Rik, potentially regulating cellular responses and gene expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K, affecting the PI3K-AKT pathway. Its interference in this cascade may indirectly impact C130039O16Rik, contributing to alterations in cell survival mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, disrupts p38 signaling. Its influence on p38 MAPK pathways can indirectly affect C130039O16Rik, potentially regulating cellular responses and gene expression. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 targets AKT in the PI3K-AKT pathway. Its inhibition of AKT may have downstream effects on C130039O16Rik, impacting cell survival and growth mechanisms. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, disrupts the MAPK pathway. By interfering with this pathway, it indirectly influences C130039O16Rik, suggesting a potential role in cellular proliferation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 targets NF-κB, impacting the NF-κB pathway. Its modulation of NF-κB pathways may indirectly influence C130039O16Rik, potentially altering gene expression and cellular responses. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190, a p38 MAPK inhibitor, disrupts p38 signaling. Its influence on p38 MAPK pathways can indirectly affect C130039O16Rik, potentially regulating cellular responses and gene expression. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 targets AKT in the PI3K-AKT pathway. Its inhibition of AKT may have downstream effects on C130039O16Rik, impacting cell survival and growth mechanisms. | ||||||